Four-year survival after trans-jugular intrahepatic porto-systemic shunt for veno-occlusive disease following autologous bone marrow transplantation

Leuk Lymphoma. 2004 Jul;45(7):1485-7. doi: 10.1080/10428190410001663626.

Abstract

Severe hepatic veno-occlusive disease is still a potentially lethal complication after bone marrow transplantation. We here report the case of a patient who developed liver veno-occlusive disease with severe hemodynamic dysfunction and was successfully treated by means of a trans-jugular intrahepatic portosystemic shunt. After three years, he is still disease-free with a functioning shunt and a normal laboratory liver profile. A trans-jugular intrahepatic portosystemic shunt is a treatment option that has been used in very few patients affected by hepatic veno-occlusive disease; its indications and timing remain to be established.

MeSH terms

  • Adult
  • Carmustine / adverse effects
  • Combined Modality Therapy
  • Cyclophosphamide / adverse effects
  • Etoposide / adverse effects
  • Hemodynamics
  • Hepatic Veno-Occlusive Disease / chemically induced
  • Hepatic Veno-Occlusive Disease / physiopathology
  • Hepatic Veno-Occlusive Disease / surgery*
  • Humans
  • Jugular Veins
  • Lymphoma, Large-Cell, Anaplastic / therapy
  • Male
  • Peripheral Blood Stem Cell Transplantation*
  • Portasystemic Shunt, Surgical*
  • Remission Induction
  • Thrombophilia / etiology
  • Transplantation Conditioning / adverse effects
  • Transplantation, Autologous

Substances

  • Etoposide
  • Cyclophosphamide
  • Carmustine